Date Filed | Type | Description |
08/21/2023 |
4
| ZIEGLER JOSEPH (Principal Financial Officer) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 7,500 shares
@ $0 |
|
08/21/2023 |
3
| ZIEGLER JOSEPH (Principal Financial Officer) has filed a Form 3 on TherapeuticsMD, Inc. |
08/18/2023 |
8-K
| Quarterly results |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/10/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
07/06/2023 |
8-K
| Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial ... |
06/30/2023 |
SC 13D/A
| Rubric Capital Management LP reports a 19.6% stake in TherapeuticsMD, Inc. |
06/29/2023 |
4
| Rubric Capital Management LP (10% Owner) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 312,525 shares
@ $3.6797, valued at
$1.1M
|
|
05/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
05/05/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
05/04/2023 |
4/A
| Walker Marlan D (CEO) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Sold 692 shares
@ $3.6381, valued at
$2.5k
Exercised 1,010 restricted stock units
@ $0 Exercised 1,734 restricted stock units
@ $0 |
|
05/01/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
04/21/2023 |
8-K
| Quarterly results |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
02/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/23/2023 |
4
| Walker Marlan D (CEO) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 70,000 restricted stock units
@ $0 |
|
02/23/2023 |
4
| Donegan Michael C (Prin. Fin. and Acctg. Officer) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Granted 50,000 restricted stock units
@ $0 |
|
02/22/2023 |
4/A
| Rubric Capital Management LP (10% Owner) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Disposed/sold 29,000 shares
@ $1333, valued at
$38.7M
|
|
02/13/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
01/30/2023 |
4
| Donegan Michael C (Prin. Fin. and Acctg. Officer) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Sold 1,648 shares
@ $5.0796, valued at
$8.4k
Sold 49 shares
@ $5.09, valued at
$249.4 Exercised 2,400 rights
@ $0 Exercised 1,140 rights
@ $0 |
|
01/25/2023 |
4
| Donegan Michael C (Prin. Fin. and Acctg. Officer) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Sold 1,302 shares
@ $5.3383, valued at
$7k
Sold 7 shares
@ $5.3101, valued at
$37.2 Exercised 380 restricted stock units
@ $0 Exercised 1,066 restricted stock units
@ $0 Exercised 519 restricted stock units
@ $0 Exercised 2,400 restricted stock units
@ $0 |
|
01/18/2023 |
8-K
| Quarterly results |
01/12/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
01/06/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
01/03/2023 |
4
| Rubric Capital Management LP (10% Owner) has filed a Form 4 on TherapeuticsMD, Inc.
Txns:
| Sold 29,000 shares
@ $1333, valued at
$38.7M
|
|
01/03/2023 |
8-K
| Resignation/termination of a director |
|